New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
You may also be interested in...
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.
FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.
FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.